The cytokines IL-1β and IL-1 receptor antagonist, IL-2 and IL-2 soluble receptor-α, IL-6 and IL-6 soluble receptor, TNF-α and TNF soluble receptor I, and IL10 in drained and systemic blood after major orthopaedic surgery

European Journal of Surgery

Volumn 165, Issue 2, 1999, Pages 101-109

  Krohn, Claus Danckert ^a   Reikerås, Olav ^b   Aasen, Ansgar O ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

Autologous transfusion; Cytokine receptors; Cytokines; Drained blood; Orthopaedic surgery

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSIVE ELEMENT; FEMALE; GRANULOCYTOSIS; HEMODILUTION; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHOCYTOSIS; MALE; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCOLIOSIS; SURGICAL INJURY; SYSTEMIC CIRCULATION; WOUND CLOSURE; BLOOD; DRUG ANTAGONISM;

ADOLESCENT; CHILD; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKINS; MALE; ORTHOPEDIC PROCEDURES; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; SCOLIOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032587621     PISSN: 11024151     EISSN: None     Source Type: Journal    
DOI: 10.1080/110241599750007261     Document Type: Article

References (27)

1. Andrejko KM, Deutschman CS. Acute-phase gene expression correlates with intrahepatic tumour necrosis factor-α abundance but not with plasma tumour necrosis factor concentrations during sepsis/systemic inflammatory response syndrome in the rat. Crit Care Med 1996; 24: 1947-1952.
2. Arnestad JP, Bengtsson A, Bengtson JP, et al. Formation of cytokines by retransfusion of shed whole blood. Br J Anaesth 1994; 72: 422-425.
3. Arnstad JP, Bengtsson A, Bengtson JP, et al. Release of cytokines, polymorphnuclear elastase and terminal C5b-9 complement complex by infusion of wound drainage blood. Acta Orthop Scand 1995; 66(4): 334-338.
4. Blevins FT, Shaw B, Valeri CR, et al. Reinfusion of shed blood after orthopaedic procedures in children and adolescents. J Bone Joint Surg 1993; 75A: 363-371.
5. Cavaillon J-M, Fitting C, Haeffner-Cavillion N. Recombinant C5a enhances interleukin 1 and tumour necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990; 20: 253-257.
6. Cruickshank AM, Fraser WD, Burns HJG, et al. Response of serum Interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci 1990; 79: 161-165.
7. Dinarello CA. Biologic basis for Interleukin-1 in disease. Blood 1996; 87: 2095-2147.
8. Faris PM, Ritter MA, Keating EM, Valeri CR. Unwashed, filtered, shed blood collected after knee and hip arthroplasties. J Bone Joint Surg 1991; 73A: 1169-1178.
9. Fong Y, Lowry SF. Tumour necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol 1990; 55: 157-170.
10. Heinrich PC, Graeve L, Rose-John S, et al. Membrane bound and soluble interleukin-6 receptor: studies on regulation of expression and signal transduction. Ann NY Acad Sci 1995; 762: 222-237.
11. Hempel L, Körholz D, Bønig H, et al. Interleukin-10 directly inhibits the interleukin production in T-cells. Scand J Immunol 1995; 41: 462-466.
12. Hirano T, Matsuda T, Nakajima K. Signal transduction through gp 130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells 1994; 12: 262-277.
13. Krohn CD, Reikerås O, Mollnes TE, Aasen AO. Complement activation and release of interleukin-6 and tumour necrosis factor-α in drained and systemic blood after major orthopaedic surgery. Eur J Surg 1998; 164: 103-108.
14. Mackiewicz A, Rose-John S, Schooltink H, et al. Soluble interleukin-6-receptor modulates interleukin-6-dependent n-glycosylation of alpha 1-protease inhibitor secreted by HepG2cells. Fed Eur Biochem Soc 1992; 306: 257-261.
15. Malefyt R de W, Abrams J, Bennet B, et al. Interleukin 10 (IL10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220.
16. Minami Y, Taniguchi T. IL-2 signalling: recruitment and activation of multiple protein tyrosine kinases by components of the IL-2 receptor. Curr Opin Cell Biol 1995; 7: 156-162.
17. Okusawa S, Dinarello CA, Yancey KB, et al. C5a induction of human interleukin 1. J Immunol 1987; 8: 2635-2640.
18. Ohmori Y, Hamilton T. Regulation of macrophage gene expression by T-cell derived lymphokines. Pharmacol Ther 1994; 63: 235-264.
19. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 227-257.
20. Rose-John S, Ehlers M, Grötzinger J, Müllberg J. The soluble Interleukin-6 receptor. Ann NY Acad Sci 1995; 762: 207-221.
21. Saatvedt K, Lindberg H, Geiran OR, et al. Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children. Scand J Clin Lab Invest 1995; 55: 79-86.
22. Schulze S, Drenck NE, Hjortsø E, Kehlet H. Influence of combined neural blockade H1-and H2-receptor and serotonin2-receptor blockade, indomethacin and tranexamic acid on leukocyte, temperature and acute-phase protein response to surgery. Acta Chir Scand 1988; 154: 329-333.
23. Schöbitz B, De Kloet ER, Halsboer F. Gene expression and function of interleukin 1, interleukin 6 and tumour necrosis factor in the brain. Prog Neurobiol 1994; 44: 397-432.
24. Stewart RJ, Marsden PA. Biologic control of the tumour necrosis factor and interleukin-1 signalling cascade. Am J Kidney Dis 1995; 25: 954-966.
25. Tang G-J, Cheng-Deng K, Tzu-Chen Y, et al. Perioperative plasma concentrations of tumour necrosis factor-α and interleukin-6 in infected patients. Crit Care Med 1996; 24: 423-428.
26. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i: 355-357.
27. Waldmann T. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993; 14: 264-270.